The Silent Shift in Pharma: From Volume to Value

For many years, growth in the pharmaceutical industry was closely associated with expansion. Larger portfolios, broader geographic coverage, and increased participation in tenders were widely viewed as indicators of strength. Scale signaled stability. A company with more products across more markets appeared less vulnerable.

Today, that logic is being quietly re-examined.

Across Europe and the MENA region, the competitive environment has matured. Healthcare systems are more data-driven, procurement processes are more analytical, and regulatory frameworks are more demanding. In this context, simply offering more products is no longer sufficient. Increasingly, success depends on how clearly a portfolio delivers value — not how broadly it is distributed.

This is the silent shift shaping pharma in 2026: a move from volume-driven growth to value-driven positioning.

Expanding a portfolio is not inherently problematic. Diversification can spread risk and open doors to new partnerships. However, unmanaged expansion often introduces operational strain.

Broader portfolios require:

• Expanded regulatory oversight across multiple jurisdictions
• More complex pharmacovigilance systems
• Greater supply chain coordination
• Increased inventory management demands
• More fragmented commercial focus

In highly regulated markets such as the EU, the administrative and compliance burden alone can become significant. In fast-evolving MENA markets, regulatory modernization and digital tracking systems are raising expectations for transparency and performance.

The result is that scale, without clear strategic intent, can dilute focus rather than strengthen resilience.

Volume creates presence. Value creates sustainability.

Healthcare systems today are under structural pressure. Aging populations, chronic disease burdens, and fiscal constraints are forcing policymakers and payers to evaluate pharmaceutical offerings more rigorously.

Reimbursement decisions increasingly depend on:

• Demonstrable real-world effectiveness
• Improved adherence outcomes
• Supply reliability
• Long-term cost efficiency
• Alignment with national healthcare priorities

In this environment, undifferentiated generics face aggressive price competition and compressed margins. At the same time, products that offer measurable clinical or operational advantages — even incremental ones — are more likely to secure stable positioning.

This does not mean that volume is irrelevant. It means that volume without differentiation is increasingly fragile.

The move toward value is reflected in how companies approach portfolio construction.

Rather than expanding broadly across therapeutic categories, leading organizations are asking more selective questions:

• Does this molecule strengthen our long-term positioning?
• Can we defend it beyond price?
• Is it aligned with regional payer expectations?
• Does it support operational excellence rather than strain it?

This is where hybrid generics and value-added medicines become strategically important. Reformulations, improved delivery systems, optimized dosing schedules, and combination therapies are not simply technical enhancements. They represent ways to elevate existing molecules into differentiated solutions.

Importantly, these strategies allow companies to balance innovation with risk management. They avoid the extreme cost and uncertainty of entirely new molecular development while still delivering measurable clinical and commercial value.

In both EU and MENA markets, this approach is proving increasingly relevant. Healthcare systems welcome solutions that improve adherence, reduce system burden, or simplify treatment pathways. These benefits resonate more strongly than catalog size.

Shifting from volume to value is not a marketing adjustment. It is a leadership decision.

It requires discipline — including the willingness to decline opportunities that do not fit strategic priorities. It means recognizing that not every molecule deserves launch, even if it appears commercially viable in isolation.

Portfolio intelligence is becoming as critical as pipeline expansion. Data analytics, supply chain forecasting, and cross-functional coordination are enabling companies to evaluate assets more holistically. When regulatory, commercial, and operational teams align early, decisions are more sustainable.

Focused portfolios also enable stronger stakeholder relationships. With fewer, more clearly positioned assets, commercial teams can communicate value more precisely. Market access discussions become more substantive. Internal resources can be allocated with greater clarity.

In a saturated industry, clarity is increasingly rare — and therefore powerful.

While the EU and MENA regions differ significantly in regulatory maturity and procurement structures, both are experiencing this shift.

In the EU, value-based procurement and stricter reimbursement frameworks reward differentiation and evidence-backed positioning.

In MENA, healthcare systems are modernizing rapidly, integrating digital infrastructure, strengthening regulatory oversight, and encouraging sustainable partnerships.

In both contexts, broad, undifferentiated portfolios are less defensible than strategically curated ones.

Scale alone no longer secures trust. Strategic fit does.

The transition from volume to value is not dramatic. It does not unfold in headlines. It is visible instead in procurement decisions, regulatory expectations, and margin compression patterns.

Companies that recognize this shift early can adapt deliberately. Those that do not may continue to grow in the short term, only to encounter structural pressure later.

In 2026, growth is no longer defined solely by the number of products launched or markets entered. It is increasingly defined by how effectively a portfolio aligns with real healthcare needs, regulatory frameworks, and operational capabilities.

Being large is not inherently an advantage. Being intentional is.